Rs12654264

Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer by Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB in Cancer Prev Res (Phila Pa). 2010 May;3(5):597-603.

The above study shows that genotyping for HMGCR rs1265464 may help identify the subset of individuals who are most likely to achieve a CRC risk reduction and cholesterol lowering with statins. Compared with individuals not taking statins, the unadjusted odds ratio of colorectal cancer among rs12654264(A;A) statin users was 0.3 (CI: 0.18-0.51) and among rs12654264(T;T) statin users, 0.66 (CI: 0.41-1.06, p-interaction 0.0012).

Their data may advance the development of personalized statin use for reducing the risk of cancer as well as cardiovascular disease among the approximately 25 million people currently using statins worldwide.


 * is_associated_with_disease::Colorectal cancer